OTC Markets OTCQX USD

Roche Holding AG (RHHBY)

34.67

+0.14

(+0.41%)

At close: June 14 at 3:59 PM EDT

Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion

Roche's (RHHBY) Alecensa gets the European Commission's approval as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer.

Zacks 4 days ago

ROG.SW
Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization

The test uses highly sensitive PCR technology, requiring only a single nasal-swab sample to provide rapid, accurate qualitative detection and differentiation among four of the most prevalent respiratory viruses for which differential diagnosis can drive appropriate treatment.Enables healthcare professionals to make confident clinical decisions and promptly determine appropriate treatment, with definitive results reported in just 20 minutes.Expands Roche’s extensive molecular point of care testin

GlobeNewswire 4 days ago

RHHBF

RHHBY
+0.41%
RHHVF
European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer

European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive resected non-small cell lung cancer, as demonstrated in the Phase III ALINA study1Alecensa’s approval addresses an urgent unmet need in the early-stage setting where about half of all people experience disease recurrence following surgery, de

GlobeNewswire 4 days ago

RHHBF

RHHBY
+0.41%
RHHVF
Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk

After five years of treatment, 91% of children were alive — without treatment, children with Type 1 SMA would not be expected to live past two years of age96% of Evrysdi-treated children could swallow, 80% could feed without a feeding tube and 59% could sit without support for at least 30 seconds Evrysdi is now approved in more than 100 countries with over 15,000 patients treated globally Basel, 07 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new five-year data confirming the s

GlobeNewswire 7 days ago

RHHBF

RHHBY
+0.41%
RHHVF
Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk

SOUTH SAN FRANCISCO, Calif., June 07, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new 5-year data confirming the sustained efficacy and safety profile of Evrysdi® (risdiplam) in children with Type 1 spinal muscular atrophy (SMA) from the open-label extension of the pivotal FIREFISH study. By the end of year 5, 91% of children treated with Evrysdi were alive, 81% were alive without permanent ventilation and the majority were able to sit without suppo

Business Wire 7 days ago

RHHBF

RHHBY
+0.41%
RHHVF
The Zacks Analyst Blog Highlights Roche, Wells Fargo, General Aerospace and Key Tronic

Roche, Wells Fargo, General Aerospace and Key Tronic are part of the Zacks top Analyst Blog.

Zacks 9 days ago

ROG.SW

KTCC
Top Analyst Reports for Roche, Wells Fargo & GE Aerospace

Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Wells Fargo & Company (WFC) and GE Aerospace (GE), as well as a micro-cap stock Key Tronic Corporation (KTCC).

Zacks 10 days ago

ROG.SW

KTCC

EOG
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study

Affimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of the AFM24/Tecentriq combo therapy to treat heavily-pretreated EGFR wild-type NSCLC patients.

Zacks 10 days ago

AFMD

ROG.SW

ALXO
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More

J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.

Zacks 14 days ago

SNY
-2.69%
AZN
+0.08%
ROG.SW
How the Moves of One Company Are Revolutionizing the Healthcare Sector

Hello, Reader. As a macro investing specialist, I look for big-picture trends that drive huge, multiyear moves in entire sectors of the market. These megatrends can spin off dozens of triple- and even quadruple-digit gains in a span of a few years. It’s not an exaggeration when I say that catching just one of these trends — at the right time — can help anyone build their wealth.InvestorPlace - Stock Market News, Stock Advice & Trading Tips And after waiting in the wings for years, artificial int

InvestorPlace 16 days ago

ROG.SW
Roche's (RHHBY) Inavolisib NDA Gets FDA Priority Review Tag

The FDA grants priority review to Roche's (RHHBY) NDA for the inavolisib combination regimen for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Zacks 16 days ago

ROG.SW

PFE
FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Priority Review recognises the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options1,2Additional analyses of INAVO120 will be presented in an oral abstract session at the 2024 American Society of Clinical Oncology Annual MeetingThe target action date for the FDA decision is 27 November, 2024 Basel, 29 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s New

GlobeNewswire 16 days ago

RHHBF

RHHBY
+0.41%
RHHVF
FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

SOUTH SAN FRANCISCO, Calif., May 29, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application and granted Priority Review to inavolisib, an investigational oral therapy, in combination with palbociclib (Ibrance®) and fulvestrant. The inavolisib-based regimen was evaluated in adult patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth fa

Business Wire 16 days ago

RHHBF

RHHBY
+0.41%
RHHVF
Roche’s Sabry retires; Duchenne drug fails confirmatory test

The veteran executive will be replaced by Boris Zaïtra. Elsewhere, Nippon Shinyaku shared negative Phase 3 data and Merck unveiled new breast cancer results for Keytruda.

BioPharma Dive 17 days ago

ROG.SW

NVS
-0.28%
Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing

Roche announced today that Hitachi High-Tech and Roche have extended their partnership, committing to at least 10 years of additional collaboration. Bringing together the companies' expertise and track record in diagnostics innovation, engineering and manufacturing, the renewed contract further strengthens the two companies' long lasting partnership.

PR Newswire 18 days ago

RHHBF

RHHBY
+0.41%
RHHVF
Changes to the Roche Enlarged Corporate Executive Committee

Basel, 27 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that James Sabry (1958), Head of Roche Pharma Partnering, will be retiring after fourteen years with the company. James Sabry joined Genentech in 2010 as Head of Genentech Partnering. In 2018, he became the Head of Pharma Partnering and a member of the enlarged Corporate Executive Committee, based in Basel, Switzerland. James Sabry completed an MD at Queen’s University in Canada and his residency at Harvard Medical School, a

GlobeNewswire 18 days ago

RHHBF

RHHBY
+0.41%
RHHVF
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More

AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.

Zacks 21 days ago

PFE

AZN
+0.08%
LLY
-0.55%
Roche’s Tina-quant Lp(a) test receives FDA breakthrough device designation

The Tina-quant Lp(a) RxDx assay is designed to identify patients who may benefit from therapies aimed at decreasing Lp(a) levels.

Medical Device Network 23 days ago

ROG.SW

AMGN
Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk

Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics Tina-quant® Lp(a) assay measures lipoprotein (a) in a person’s bloodstream, and will be made available on Roche’s installed base of over 90,000 serum work area (SWA) systems worldwide. The test has been developed in collaboration with Amgen. Basel, 22 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announc

GlobeNewswire 23 days ago

RHHBF

RHHBY
+0.41%
RHHVF
Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation

Roche's (RHHBY) inavolisib gets Breakthrough Therapy Designation in the United States for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Zacks 24 days ago

ROG.SW

Performance Overview

Return	RHHBY	MSCI WORLD
YTD	-0.25%	+10.19%
1-Year	-6.68%	+19.19%
3-Year	-19.06%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Roche Holding AG (RHHBY)

Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion

Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization

European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer

Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk

Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk

The Zacks Analyst Blog Highlights Roche, Wells Fargo, General Aerospace and Key Tronic

Top Analyst Reports for Roche, Wells Fargo & GE Aerospace

Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study

Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More

How the Moves of One Company Are Revolutionizing the Healthcare Sector

Roche's (RHHBY) Inavolisib NDA Gets FDA Priority Review Tag

FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Roche’s Sabry retires; Duchenne drug fails confirmatory test

Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing

Changes to the Roche Enlarged Corporate Executive Committee

Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More

Roche’s Tina-quant Lp(a) test receives FDA breakthrough device designation

Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk

Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation

Performance Overview